

Correction

Correction: van Veelen et al. First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study. *J. Clin. Med.* 2023, 12, 5807

Anna van Veelen ¹, I. Tarik Küçük ¹, Federico H. Fuentes ², Yirga Kahsay ², Hector M. Garcia-Garcia ², Ronak Delewi ¹, Marcel A. M. Beijk ¹, Alexander W. den Hartog ¹, Maik J. Grundeken ¹, M. Marije Vis ¹, José P. S. Henriques ¹ and Bimmer E. P. M. Claessen ^{1,*}

¹ Heart Center, Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, 1105 AZ Amsterdam, The Netherlands; i.t.kucuk@amsterdamumc.nl (I.T.K.); r.delewi@amsterdamumc.nl (R.D.); m.a.beijk@amsterdamumc.nl (M.A.M.B.); a.w.denhartog@amsterdamumc.nl (A.W.d.H.); m.j.grundeken@amsterdamumc.nl (M.J.G.); m.m.vis@amsterdamumc.nl (M.M.V.); j.p.henriques@amsterdamumc.nl (J.P.S.H.)

² MedStar Washington Hospital Center, Washington, DC 20010, USA; federico.h.fuentes@medstar.net (F.H.F.); yirga.kahsay@medstar.net (Y.K.); hector.m.garciagarcia@medstar.net (H.M.G.-G.)

* Correspondence: b.e.claessen@amsterdamumc.nl; Tel.: +31-20-566-9111

1. Text Correction

In the original publication [1], there was a mistake in Section 2.8. Statistical Considerations, Paragraph 1. The corrected version of Section 2.8. Statistical Considerations, Paragraph 1 appears below:

Continuous baseline demographic and clinical variables will be presented in terms of percentiles (e.g., median, 25th, and 75th percentile or mean with standard deviation), while categorical variables are summarized in terms of frequencies and percentages. All *p*-values will be two-sided and a *p*-value of <0.05 will be considered statistically significant. The primary endpoint will be core-lab adjudicated and analyzed on both the lesion-level and the patient-level using a paired samples test. Missing data will be excluded from the analysis. The secondary endpoints will be summarized in frequencies and percentages.

2. Error in Table

In the original publication [1], there was a mistake in Table 3, as published. The corrected version of Table 3 appears below.

Table 3. Baseline characteristics.

	PE-DCB (n = 20)
Age, (years)	66 (55–73)
Male	18 (90%)
Body mass index, (kg/m ²)	26.4 (23.3–36.4) *
Current tobacco use	3 (15%) **
Chronic obstructive pulmonary disease	1 (5%)
Diabetes mellitus	1 (5%)
Hypertension	11 (55%)
Hypercholesterolemia	12 (60%)
Family history of coronary artery disease	5 (39%) ***
Prior myocardial infarction	3 (15%)
Prior percutaneous coronary intervention	3 (15%)
Prior bypass graft surgery	0 (0%)
Prior stroke	1 (5%)
Laboratory measures	
Total cholesterol, (mmol/L)	5.0 (4.2–6.4) ****
High-density lipoprotein, (mmol/L)	1.1 (1.0–1.3) *****
Low-density lipoprotein, (mmol/L)	2.8 (2.2–4.0) *****
Triglycerides, (mmol/L)	1.9 (1.2–2.6) *****
Hemoglobin, (mmol/L)	9.3 (8.7–10.1)
Leucocytes, (×10 ⁹ /L)	7.7 (6.2–11.4) *****
Thrombocytes, (×10 ⁹ /L)	204 (188–221)
Lipid-lowering medication prior to admission	
Statin	9 (45%)
Ezetimibe	9 (45%)
PCSK9 inhibitor	0 (0%)

Numbers are presented as median (interquartile range) or numbers (percentages). PCSK9 denotes proprotein convertase subtilisin/kexin type 9. * Data available from 11 patients. ** Data available from 15 patients. *** Data available from 13 patients. **** Data available from 7 patients. ***** Data available from 6 patients. ***** Data available from 19 patients.



Citation: van Veelen, A.; Küçük, I.T.; Fuentes, F.H.; Kahsay, Y.; Garcia-Garcia, H.M.; Delewi, R.; Beijk, M.A.M.; den Hartog, A.W.; Grundeken, M.J.; Vis, M.M.; et al. Correction: van Veelen et al.

First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study. *J. Clin. Med.* 2023, 12, 5807. *J. Clin. Med.* 2024, 13, 1479. <https://doi.org/10.3390/jcm13051479>

Received: 5 February 2024

Accepted: 19 February 2024

Published: 4 March 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

1. van Veelen, A.; Küçük, I.T.; Fuentes, F.H.; Kahsay, Y.; García-García, H.M.; Delewi, R.; Beijk, M.A.M.; Den Hartog, A.W.; Grundeken, M.J.; Vis, M.M.; et al. First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study. *J. Clin. Med.* **2023**, *12*, 5807. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.